included in the study. The proportion of hypothyroidism amongst GCA patients was increased in comparison with controls (18.2% vs. 6.91%, respectively, p-value <0.001) , as was hyperthyroidism (2. 56% and 1.19% respectively, pvalue <0.001) . After controlling for confounders, GCA demonstrated a robust independent association with hypothyroidism on multivariate logistic regression (OR 1.297, 95% CI 1.187-1.418, Table 1 ). In contrast, when a similar model was performed in order to assess the nature of the association between GCA and hyperthyroidism, it was found to be non-significant, with an OR of 1.097. Background: Behcet's disease is a multisystemic chronic relapsing inflammatory disease, classified among the vasculitides. The aetiology of Behcet's disease is unknown. Several cytokines, among them TNF-α, are involved in the pathogenesis of the disease. Objectives: We aimed to assess efficacy and safety of Adalimumab (ADA) in patients with active Behcet's arthritis not responding to one or more DMARDS and to assess the impact of treatment on the cytokine milieu. Methods: Eligible patients (pts) with active arthritis were enrolled in a 24 weeks single center prospective open-label study. Pts who relapsed within 12 weeks following ADA discontinuation could enter a 3 year extension study. The efficacy was assessed by 68 tender and 66 swollen joint count, patient visual analogue scale (VAS) for pain, physician overall disease activity VAS, health assessment questionnaire (HAQ), Behçet's Disease Current Activity Form (BDCAF), C reactive protein (CRP) and erythrocyte sedimentation rate (ESR). TNF-α,IL-1β, IL-6, INF-γ, IL-10 and IL-17a were evaluated at baseline, after 24 and 48 weeks of treatment, by ProcartaPlex Human High Sensitivity -Immunoassay kit. Trough ADA serum levels and anti-drug antibodies were measured at baseline, week 24 and 48. Results: Ten pts (6 females),age (mean, standard deviation -SD) 45 (8.4) years, with a disease duration of 11.6 (10) years, were enrolled and treated with subcutaneous ADA 40mg every 2 weeks for 24 weeks. The results are described Abstract THU0344 - ADA serum trough levels were in the therapeutic range in 7/10 pts. One patient developed high antidrug antibodies titer and ADA serum trough level of 0 with a concomitant increase in VAS pain and IL-6 concentration. Another patient with low ADA trough levels and no antibodies improved after providing ADA weekly. The disease relapsed in 9/10 pts, within 4-6 weeks following ADA interruption, 7 pts enrolled into the extension study. [2010] [2011] [2012] , rate of referrals for TAB per month declined to 0.78, the proportion of patients having a TAB within 14 days of referral reached 100%, and the proportion of patients with a positive biopsy increased to 30% suggesting appropriate use of the pathway and an improvement in care. However introducing a non-rheumatology led GCA pathway (2012-2016), led to increased referral numbers. The proportion of TAB within 14 days decreased, and the proportion with a positive biopsy declined (17%).
The non-rheumatology led GCA pathway was associated with higher glucocorticoid burden. 2010 golimumab, 2011 etanercept, 2012 etanercept, 2013 golimumab, 2014 certolizumab, 2015 certolizumab/biosimilar infliximab (CT-P13). We compared the estimated change in Ankylosing Spondylitis Disease Activity Score (ASDAS) between treatment years at 3, 6 and 12 months after treatment start using a mixed model with subject-specific random intercept, adjusting for baseline disease activity, age, sex and treatment centre. Results: Demographics, drug uptake and baseline characteristics for each year 2009-2015 are listed in table 1. The preferred drug was started in 57-91% of patients. There was a trend towards lower ASDAS and disease duration over time. There were no differences in treatment effectiveness between the years, regardless of the substantial differences in type of TNFi used ( figure) . Conclusions: Real-life data do not show differences in response to TNFi despite large annual variation in type of TNFi prescribed, indicating similar effectiveness of the available TNFi in patients with axSpA. This supports the practice of selecting drug based on cost and feasibility of use, as is the current practice in Norway. Further adoption of this principle can provide access to TNFi treatment to more patients, as it reduces costs and healthcare resources are limited. 
